The number of studies that focus on psychedelics and the benefits they possess as therapies for various mental health conditions has increased tremendously in the last few years. Psychedelics such as LSD and psilocybin mushrooms have shown their potential as possible therapies for conditions such as depression and PTSD, and while many hope that these drugs will be approved as therapies soon, there are those who are concerned about the effects these drugs may have on patients who participate in clinical trials for their study.
New research has identified traits that have been linked to negative and positive experiences on psychedelics from prior studies. This data could help forecast how participants of clinical trials will respond to psychedelic drugs in the future.
The discoveries suggest that individuals who are apprehensive or preoccupied may likely experience challenging or negative experiences from taking psychedelics while those who are able to surrender to the unknown and are more open to new experiences are likely to have a positive experience while on these mind-altering substances. Researchers note that these forecasts could be utilized by scientists to help clinical trial patients who feel hesitant be more open to therapy, perhaps by providing lower doses to begin with.
The study’s senior author and Ohio State University assistant professor of social work Alan Davis stated that their findings signaled various things that the researchers could investigate in the future, noting that it would be reasonable to administer threshold doses that were smaller than those administered in trials as a first exposure. By doing so, individuals would experience less anxiety, and once they felt the benefits, a higher dose could be administered next time.
The review was reported in the “ACS Pharmacology & Translational Science” journal, online.
The researchers analyzed 14 clinical trials and other studies carried out in the recent years that recorded the states of mind or the personality traits of their participants, as well as their associations with negative or positive experiences on psychedelics.
A Central Michigan University PhD psychology candidate Jacob Aday, who was the first author of the study, explained that for the longest time, researchers involved in the field of psychedelics had questioned how they could forecast how individuals would react to these mind-altering substances.
Prior evidence suggests that psychedelics may be efficacious in treating substance use, trauma-based, anxiety and mood disorders.
Davis noted that individuals who had experienced trauma weren’t very big on surrendering to the experience while those who had absorption, acceptance and openness traits would likely experience ego dissolution.
Aday stated that they found no differences based on sex, noting that women and men both responded similarly.
The findings of this study are a valuable addition to the R&D efforts of companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which is involved in identifying how various psychedelic substances, including DMT and psilocybin, can be used therapeutically.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.